Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvant

Chun Yu Tung, David E. Lewis, Ling Han, Morayo Jaja, Shuyu Yao, Fang Li, Michael J. Robertson, Baohua Zhou, Jie Sun, Hua Chen Chang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The addition of an appropriate adjuvant that activates the innate immunity is essential to subsequent development of the adaptive immunity specific to the vaccine antigens. Thus, any innovation capable of improving the immune responses may lead to a more efficacious vaccine. We recently identified a novel immune modulator using a naturally occurring seed peptide called lunasin. Lunasin was originally isolated from soybeans, and it is a small peptide containing 43 amino acids. Our studies revealed stimulatory effects of lunasin on innate immune cells by regulating expression of a number of genes that are important for immune responses. The objective was to define the effectiveness of lunasin as an adjuvant that enhances immune responses. The immune modulating functions of lunasin were characterized in dendritic cells (DCs) from human peripheral blood mononuclear cells (PBMCs). Lunasin-treated conventional DCs (cDCs) not only expressed elevated levels of co-stimulatory molecules (CD86, CD40) but also exhibited up-regulation of cytokines (IL1B, IL6) and chemokines (CCL3, CCL4). Lunasin-treated cDCs induced higher proliferation of allogeneic CD4+ T cells when comparing with medium control treatment in the mixed leukocyte reaction (MLR). Immunization of mice with ovalbumin (OVA) and lunasin inhibited the growth of OVA-expressing A20 B-lymphomas, which was correlated with OVA-specific CD8+ T cells. In addition, lunasin was an effective adjuvant for immunization with OVA, which together improved animal survival against lethal challenge with influenza virus expressing the MHC class I OVA peptide SIINFEKL (PR8-OTI). These results suggest that lunasin may function as a vaccine adjuvant by promoting DC maturation, which in turn enhances the development of protective immune responses to the vaccine antigens.

Original languageEnglish (US)
Pages (from-to)5411-5419
Number of pages9
JournalVaccine
Volume32
Issue number42
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

vaccine adjuvants
ovalbumin
Ovalbumin
dendritic cells
Dendritic Cells
Vaccines
immune response
adjuvants
peptides
vaccines
Immunization
immunization
T-lymphocytes
Chemokine CCL4
antigens
Chemokine CCL3
T-Lymphocytes
Antigens
Peptides
Mixed Lymphocyte Culture Test

Keywords

  • DC maturation
  • Immune modulating agent
  • Lunasin
  • Vaccine adjuvant

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Tung, C. Y., Lewis, D. E., Han, L., Jaja, M., Yao, S., Li, F., ... Chang, H. C. (2014). Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvant. Vaccine, 32(42), 5411-5419. https://doi.org/10.1016/j.vaccine.2014.07.103

Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvant. / Tung, Chun Yu; Lewis, David E.; Han, Ling; Jaja, Morayo; Yao, Shuyu; Li, Fang; Robertson, Michael J.; Zhou, Baohua; Sun, Jie; Chang, Hua Chen.

In: Vaccine, Vol. 32, No. 42, 01.01.2014, p. 5411-5419.

Research output: Contribution to journalArticle

Tung, CY, Lewis, DE, Han, L, Jaja, M, Yao, S, Li, F, Robertson, MJ, Zhou, B, Sun, J & Chang, HC 2014, 'Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvant', Vaccine, vol. 32, no. 42, pp. 5411-5419. https://doi.org/10.1016/j.vaccine.2014.07.103
Tung, Chun Yu ; Lewis, David E. ; Han, Ling ; Jaja, Morayo ; Yao, Shuyu ; Li, Fang ; Robertson, Michael J. ; Zhou, Baohua ; Sun, Jie ; Chang, Hua Chen. / Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvant. In: Vaccine. 2014 ; Vol. 32, No. 42. pp. 5411-5419.
@article{8bd574f71e3446c2bc0e2856d6919fa0,
title = "Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvant",
abstract = "The addition of an appropriate adjuvant that activates the innate immunity is essential to subsequent development of the adaptive immunity specific to the vaccine antigens. Thus, any innovation capable of improving the immune responses may lead to a more efficacious vaccine. We recently identified a novel immune modulator using a naturally occurring seed peptide called lunasin. Lunasin was originally isolated from soybeans, and it is a small peptide containing 43 amino acids. Our studies revealed stimulatory effects of lunasin on innate immune cells by regulating expression of a number of genes that are important for immune responses. The objective was to define the effectiveness of lunasin as an adjuvant that enhances immune responses. The immune modulating functions of lunasin were characterized in dendritic cells (DCs) from human peripheral blood mononuclear cells (PBMCs). Lunasin-treated conventional DCs (cDCs) not only expressed elevated levels of co-stimulatory molecules (CD86, CD40) but also exhibited up-regulation of cytokines (IL1B, IL6) and chemokines (CCL3, CCL4). Lunasin-treated cDCs induced higher proliferation of allogeneic CD4+ T cells when comparing with medium control treatment in the mixed leukocyte reaction (MLR). Immunization of mice with ovalbumin (OVA) and lunasin inhibited the growth of OVA-expressing A20 B-lymphomas, which was correlated with OVA-specific CD8+ T cells. In addition, lunasin was an effective adjuvant for immunization with OVA, which together improved animal survival against lethal challenge with influenza virus expressing the MHC class I OVA peptide SIINFEKL (PR8-OTI). These results suggest that lunasin may function as a vaccine adjuvant by promoting DC maturation, which in turn enhances the development of protective immune responses to the vaccine antigens.",
keywords = "DC maturation, Immune modulating agent, Lunasin, Vaccine adjuvant",
author = "Tung, {Chun Yu} and Lewis, {David E.} and Ling Han and Morayo Jaja and Shuyu Yao and Fang Li and Robertson, {Michael J.} and Baohua Zhou and Jie Sun and Chang, {Hua Chen}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.vaccine.2014.07.103",
language = "English (US)",
volume = "32",
pages = "5411--5419",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "42",

}

TY - JOUR

T1 - Activation of dendritic cell function by soypeptide lunasin as a novel vaccine adjuvant

AU - Tung, Chun Yu

AU - Lewis, David E.

AU - Han, Ling

AU - Jaja, Morayo

AU - Yao, Shuyu

AU - Li, Fang

AU - Robertson, Michael J.

AU - Zhou, Baohua

AU - Sun, Jie

AU - Chang, Hua Chen

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The addition of an appropriate adjuvant that activates the innate immunity is essential to subsequent development of the adaptive immunity specific to the vaccine antigens. Thus, any innovation capable of improving the immune responses may lead to a more efficacious vaccine. We recently identified a novel immune modulator using a naturally occurring seed peptide called lunasin. Lunasin was originally isolated from soybeans, and it is a small peptide containing 43 amino acids. Our studies revealed stimulatory effects of lunasin on innate immune cells by regulating expression of a number of genes that are important for immune responses. The objective was to define the effectiveness of lunasin as an adjuvant that enhances immune responses. The immune modulating functions of lunasin were characterized in dendritic cells (DCs) from human peripheral blood mononuclear cells (PBMCs). Lunasin-treated conventional DCs (cDCs) not only expressed elevated levels of co-stimulatory molecules (CD86, CD40) but also exhibited up-regulation of cytokines (IL1B, IL6) and chemokines (CCL3, CCL4). Lunasin-treated cDCs induced higher proliferation of allogeneic CD4+ T cells when comparing with medium control treatment in the mixed leukocyte reaction (MLR). Immunization of mice with ovalbumin (OVA) and lunasin inhibited the growth of OVA-expressing A20 B-lymphomas, which was correlated with OVA-specific CD8+ T cells. In addition, lunasin was an effective adjuvant for immunization with OVA, which together improved animal survival against lethal challenge with influenza virus expressing the MHC class I OVA peptide SIINFEKL (PR8-OTI). These results suggest that lunasin may function as a vaccine adjuvant by promoting DC maturation, which in turn enhances the development of protective immune responses to the vaccine antigens.

AB - The addition of an appropriate adjuvant that activates the innate immunity is essential to subsequent development of the adaptive immunity specific to the vaccine antigens. Thus, any innovation capable of improving the immune responses may lead to a more efficacious vaccine. We recently identified a novel immune modulator using a naturally occurring seed peptide called lunasin. Lunasin was originally isolated from soybeans, and it is a small peptide containing 43 amino acids. Our studies revealed stimulatory effects of lunasin on innate immune cells by regulating expression of a number of genes that are important for immune responses. The objective was to define the effectiveness of lunasin as an adjuvant that enhances immune responses. The immune modulating functions of lunasin were characterized in dendritic cells (DCs) from human peripheral blood mononuclear cells (PBMCs). Lunasin-treated conventional DCs (cDCs) not only expressed elevated levels of co-stimulatory molecules (CD86, CD40) but also exhibited up-regulation of cytokines (IL1B, IL6) and chemokines (CCL3, CCL4). Lunasin-treated cDCs induced higher proliferation of allogeneic CD4+ T cells when comparing with medium control treatment in the mixed leukocyte reaction (MLR). Immunization of mice with ovalbumin (OVA) and lunasin inhibited the growth of OVA-expressing A20 B-lymphomas, which was correlated with OVA-specific CD8+ T cells. In addition, lunasin was an effective adjuvant for immunization with OVA, which together improved animal survival against lethal challenge with influenza virus expressing the MHC class I OVA peptide SIINFEKL (PR8-OTI). These results suggest that lunasin may function as a vaccine adjuvant by promoting DC maturation, which in turn enhances the development of protective immune responses to the vaccine antigens.

KW - DC maturation

KW - Immune modulating agent

KW - Lunasin

KW - Vaccine adjuvant

UR - http://www.scopus.com/inward/record.url?scp=84922400219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922400219&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.07.103

DO - 10.1016/j.vaccine.2014.07.103

M3 - Article

C2 - 25131731

AN - SCOPUS:84922400219

VL - 32

SP - 5411

EP - 5419

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 42

ER -